ALS Therapeutic Target Characterization Service

Amyotrophic lateral sclerosis (ALS) affects over 700,000 people globally, and current therapies fail to prevent functional decline. Our CRO specializes in neurobiology, providing ALS therapeutic target characterization services. We combine multiomics analysis, system biology validation, and preclinical model testing to facilitate the development of breakthrough therapies. For further information regarding the products and services provided, project-specific consultation, and pricing, please submit an inquiry here.

Biomarkers of ALS

The ability to accurately predict disease progression, assess prognosis, and tailor treatment strategies in ALS hinges on a deep understanding of relevant biomarkers. Key markers, including RNA-binding proteins (RBPs), ALS-related genes, and non-coding RNAs, provide critical insights into the disease's complexities. We offer specialized characterization analysis services for these crucial ALS markers, detailed below:

Fig.1 Population analysis and validation of iPSC-derived motor neuron differentiation using single-cell RNA-seq.¹

Multi-Model Validation System

Accelerate your ALS research with our integrated, full-process validation platform, designed to rigorously evaluate therapeutic targets across multiple levels, from cellular mechanisms to in vivo efficacy.

• Humanized iPS cell model: Uses patient-derived motor neurons to verify the function of the target.
• Drosophila model: The c9ALS Drosophila eye degeneration scoring system is used to rapidly verify the direct effect of the target on neurodegeneration.
• Transgenic mouse model: Includes SOD1, TDP-43, FUS and other mutant models used to evaluate the ameliorative effect of the target on motor function and survival.

AI-Powered Screening

Revolutionize your ALS therapeutic development with our AI-driven target screening services. We leverage a world-leading artificial intelligence platform, integrating advanced AI technology to intelligently analyze the complex genomic, transcriptomic, and proteomic data from ALS patients. Through sophisticated deep learning models, we rapidly identify high-confidence drug targets, providing a robust scientific foundation for your new drug development initiatives.

If you require further technical details or customized solutions, please contact our technical support team for assistance and service offerings. We are committed to providing cost-effective target validation solutions for ALS drug development by integrating cutting-edge technologies.

Reference

1. Chun, Changho, et al. "Human Motor Neurons Elicit Pathological Hallmarks of ALS and Reveal Potential Biomarkers of the Disease in Response to Prolonged IFNγ Exposure." Journal of Neuroscience 44.16 (2024). Distributed under Open Access license CC BY 4.0, without modification.